CELGENE CORP /DE/ 4
4 · ACCELERON PHARMA INC · Filed Jul 13, 2020
Insider Transaction Report
Form 4
CELGENE CORP /DE/
10% Owner
Transactions
- Exercise of In-Money
Common Stock
2020-07-09$5.88/sh+38,979$229,197→ 7,010,751 total - Exercise of In-Money
Option Warrant
2020-07-09−38,979→ 0 totalExercise: $5.88Exp: 2020-07-09→ Common Stock, $0.001 par value (38,979 underlying) - Sale
Common Stock
2020-07-09$102.28/sh−2,241$229,209→ 7,008,510 total
Footnotes (4)
- [F1]This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company (the "Reporting Persons").
- [F2]These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities.
- [F3]On July 9, 2020, the Reporting Persons exercised a warrant to purchase 38,979 shares of the Issuer's common stock for $5.88 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,241 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 36,738 shares.
- [F4]All of the shares are currently exercisable.